Non-alcoholic Fatty Liver Disease
Pipeline by Development Stage
Drug Modality Breakdown
Metabolic Diseases is a $70.5B mature market dominated by diabetes and anticoagulation therapies with sustained blockbuster momentum.
Key Trends
- GLP-1 agonists (Ozempic, Mounjaro) driving explosive growth and market consolidation
- SGLT2 inhibitors expanding beyond diabetes into cardio-renal indications
- Significant patent cliff risk 2027-2029 for DPP-4 inhibitors (Januvia) and older insulins
Career Verdict
Excellent opportunity for specialists seeking stable, high-revenue exposure with strong hiring momentum in commercial and engineering roles.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 26% | Launch | Stable | 15.0yr |
| 2 | OZEMPIC (semaglutide) | Novo Nordisk | $9.2B | 13% | Peak | Growing | 12.4yr |
| 3 | JARDIANCE (empagliflozin) | Boehringer Ingelheim | $8.8B | 12% | Peak | Growing | 8.6yr |
| 4 | TRULICITY (dulaglutide) | Eli Lilly and Company | $7.4B | 10% | Peak | Stable | |
| 5 | FARXIGA (dapagliflozin) | AstraZeneca | $4.3B | 6% | Peak | Growing | 15.4yr |
Drug Class Breakdown
stable, mature franchise
rapid growth, expanding indications
growing, cardio-renal expansion
stable, generics pressure
declining, patent cliff 2027
Career Outlook
GrowingMetabolic diseases offers stable, high-value career trajectory with blockbuster product revenue supporting competitive compensation and long-term job security. Commercial and field-based roles dominate hiring, reflecting the shift toward patient access, digital health, and device integration in diabetes management. Patent cliff exposure in DPP-4 class (2027-2029) creates near-term volatility for Merck but limited impact on overall market given GLP-1 dominance.
Breaking In
Target device companies (Insulet, Abbott) or diagnostic firms for entry-level roles if traditional pharma hiring is limited; strong foundation in diabetes biology and HbA1c/CGM metrics will accelerate credibility.
For Experienced Professionals
Experienced professionals should prioritize GLP-1 franchise or SGLT2 indication expansion roles; avoid Merck DPP-4-focused assignments given 2027 patent cliff, unless willing to transition to next-generation pipeline.
In-Demand Skills
Best For
Hiring Landscape
Hiring activity is concentrated in commercial roles (166 positions) and engineering (126 positions), driven by device makers (Insulet: 270 jobs) and diagnostic companies (Abbott: 154 jobs) rather than traditional pharma. Sanofi leads pharma hiring with 42 metabolic-focused positions, but specialized roles in clinical operations remain constrained. Salary expectations range from $153K (Clinical Ops) to $274K (Manufacturing), with strong compensation for commercial and quality roles.
Top Hiring Companies
By Department
Strongest hiring momentum in device/delivery and commercial infrastructure; traditional pharma R&D roles remain limited despite blockbuster pipeline.
Competitive Landscape
28 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 40 trials with date data
Clinical Trials (40)
Total enrollment: 5,457 patients across 40 trials
The Efficacy and Safety of Ornithine Aspartic Acid Granules in NAFLD Against Silymarin Capsules
Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis
Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
Levothyroxine for Non-Alcoholic Fatty Liver Disease (NAFLD)
Safety and Efficacy of HL Tablet in Non-alcoholic Fatty Liver Disease Patients
Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis
PK of NRL972 in Patients with Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)
Effects of Probiotics (P. Pentosaceus, L. Lactis or L. Helveticus) in NASH
A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease
A Research Study Looking at How a Single Dose of the Medicine NNC0194-0499 Behaves in Chinese Men
Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease
Study in Healthy Adults Evaluating PF-07202954
The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Subjects
Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan
Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects
Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)
FibroScan-Reproducibility and Repeatability Study
The Metabolic Effects of Ginseng Oligopeptide Preparation on Non- Alcoholic Fatty Liver Disease With Obesity: a Randomized Controlled Double-blind Trial
Lysosomal Acid Lipase Activity in Nonalcoholic Fatty Liver Disease
Electrical Impedance Tomography in Fatty Liver Detection
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
Ectopic Fat in Singaporean Women - the Culprit Leading to Gestational Diabetes, Metabolic Syndrome, and Type 2 Diabetes (TANGO Study)
Pediatric Liver Fat Quantification (LFQ) Phase 2 Pilot Study
The Effect of Lifestyle-induced Hepatic Steatosis on Glucagon-stimulated Amino Acid Turnover
Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study
Mediterranean Diet Versus Paleolithic Diet for the Treatment of Non Alcohlic Fatty Liver Disease
Super HEROES: Searching How the Extract Rebaudioside Occludes Excess Steatosis
NAFLD Among Patients With Chronic Kidney Disease and the Effect of Kidney Transplantation
Technical Validation of MR Biomarkers of Obesity-Associated NAFLD
A Prospective Study of HBV Immunity and HBV Vaccination in Patients With NAFLD in Canada
Prospective, Cross-sectional and Multicenter Study, Evaluating the Diagnosis Accuracy of the Controlled Attenuation Parameter(CAP) Measured by FibroScan® (Either With M+ or XL+ Probe) in Patient With Non-Alcoholic Fatty Liver Disease Using Liver Biopsy as Reference.
Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk
Related Jobs in Metabolic Diseases
Gastroenterology Health & Science Sales Specialist - Allentown, PA
Gastroenterology Health & Science Sales Specialist - Melbourne, FL
Medical Specialist I (Gastro)
Medical Specialist I (Gastro)-Long Beach, Ca
Medical Specialist I (Gastro) - Kansas City, MO
RA/Gastroenterology, Medical Affairs Scientist, Medical Manager/Associate (Field Medical)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.